Interestingly, the change of SAA level (ΔSAA) from baseline to 6 months was significantly higher in patients with RA who were treated with Tocilizumab than in those treated with JAKi and csDMARDs (Figure 10C and Supplemental Figure 12). The gene discussed is SAA2; the disease is rheumatoid arthritis.